Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months

被引:30
作者
Stuart, Arabella S., V [1 ]
Virta, Miia [2 ]
Williams, Kristi [3 ]
Seppa, Ilkka [2 ]
Hartvickson, Robyn [4 ]
Greenland, Melanie [1 ]
Omoruyi, Edmund [5 ]
Bastian, Arangassery Rosemary [3 ]
Haazen, Wouter [3 ]
Salisch, Nadine [3 ]
Gymnopoulou, Efi [5 ]
Callendret, Benoit [3 ]
Faust, Saul N. [6 ,7 ,8 ]
Snape, Matthew D. [1 ,9 ]
Heijnen, Esther [3 ]
机构
[1] Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford, England
[2] Tampere Univ, Tampere, Finland
[3] Janssen Vaccines & Prevent BV, NL-2333 CN Leiden, Netherlands
[4] Axtell Clin, Newton, KS USA
[5] Janssen Infect Dis, Beerse, Belgium
[6] Univ Hosp Southampton NHS Fdn Trust, NIHR Southampton Clin Res Facil, Southampton, Hants, England
[7] Univ Hosp Southampton NHS Fdn Trust, NIHR Biomed Res Ctr, Southampton, Hants, England
[8] Univ Southampton, Fac Med & Inst Life Sci, Southampton, Hants, England
[9] Oxford Univ Hosp NHS Fdn Trust, Oxford NIHR Biomed Res Ctr, Oxford, England
关键词
adenovirus vectors; pediatric; respiratory syncytial virus; seropositive; vaccine; PREVENTION; NIRSEVIMAB; INFECTION; PRETERM; PROTEIN; DISEASE; OLDER;
D O I
10.1093/infdis/jiac407
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A novel Ad26 vector-based RSV vaccine encoding preF-protein given as 2 doses in a double-blind RCT of 12 adults and 36 RSV-seropositive toddlers showed acceptable safety and tolerability up to 1 year, with evidence of humoral and cellular immunogenicity. Background Respiratory syncytial virus (RSV) remains a leading cause of pediatric morbidity, with no approved vaccine. We assessed the safety and immunogenicity of the Ad26.RSV.preF vaccine candidate in adults and children. Methods In this randomized, double-blind, phase 1/2a, placebo-controlled study, 12 adults (18-50 years) and 36 RSV-seropositive children (12-24 months) were randomized 2:1 to Ad26.RSV.preF (1 x 10(11) viral particles [vp] for adults, 5 x 10(10) vp for children) or placebo, at day 1 and 29, with 6-month immunogenicity and 1-year safety follow-up. Respiratory syncytial virus infection was an exploratory outcome in children. Results In adults, solicited adverse events (AEs) were generally mild to moderate, with no serious AEs. In children, no vaccination-related serious AEs were reported; fever was reported in 14 (58.3%) Ad26.RSV.preF recipients. Baseline pediatric geometric mean titers for RSV A2 neutralization increased from 121 (95% confidence interval [CI], 76-191) to 1608 (95% CI, 730-3544) at day 29, and 2235 (95% CI, 1586-3150) at day 57, remaining elevated over 7 months. Respiratory syncytial virus infection was confirmed in fewer children receiving Ad26.RSV.preF (1, 4.2%) than placebo (5, 41.7%). Conclusions Ad26.RSV.preF demonstrated immunogenicity in healthy adults and toddlers, with no safety concerns raised. Evaluations in RSV-seronegative children are underway.
引用
收藏
页码:71 / 82
页数:12
相关论文
共 30 条
[1]   Strategic priorities for respiratory syncytial virus (RSV) vaccine development [J].
Anderson, L. J. ;
Dormitzer, P. R. ;
Nokes, D. J. ;
Rappuoli, R. ;
Roca, A. ;
Graham, B. S. .
VACCINE, 2013, 31 :B209-B215
[2]  
[Anonymous], STUD EV SAF REACT IM
[3]   Adults 65 Years Old and Older Have Reduced Numbers of Functional Memory T Cells to Respiratory Syncytial Virus Fusion Protein [J].
Cherukuri, Anu ;
Patton, Kathryn ;
Gasser, Robert A., Jr. ;
Zuo, Fengrong ;
Woo, Jennifer ;
Esser, Mark T. ;
Tang, Roderick S. .
CLINICAL AND VACCINE IMMUNOLOGY, 2013, 20 (02) :239-247
[4]   First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults [J].
Cicconi, Paola ;
Jones, Claire ;
Sarkar, Esha ;
Silva-Reyes, Laura ;
Klenerman, Paul ;
de Lara, Catherine ;
Hutchings, Claire ;
Moris, Philippe ;
Janssens, Michel ;
Fissette, Laurence A. ;
Picciolato, Marta ;
Leach, Amanda ;
Gonzalez-Lopez, Antonio ;
Dieussaert, Ilse ;
Snape, Matthew D. .
CLINICAL INFECTIOUS DISEASES, 2020, 70 (10) :2073-2081
[5]  
ClinicalTrials.gov, STUD EV SAF EFF MED1
[6]   A proof of concept for structure-based vaccine design targeting RSV in humans [J].
Crank, Michelle C. ;
Ruckwardt, Tracy J. ;
Chen, Man ;
Morabito, Kaitlyn M. ;
Phung, Emily ;
Costner, Pamela J. ;
Holman, LaSonji A. ;
Hickman, Somia P. ;
Berkowitz, Nina M. ;
Gordon, Ingelise J. ;
Yamshchikov, Galina V. ;
Gaudinski, Martin R. ;
Kumar, Azad ;
Chang, Lauren A. ;
Moin, Syed M. ;
Hill, Juliane P. ;
DiPiazza, Anthony T. ;
Schwartz, Richard M. ;
Kueltzo, Lisa ;
Cooper, Jonathan W. ;
Chen, Peifeng ;
Stein, Judith A. ;
Carlton, Kevin ;
Gall, Jason G. ;
Nason, Martha C. ;
Kwong, Peter D. ;
Chen, Grace L. ;
Mascola, John R. ;
McLellan, Jason S. ;
Ledgerwood, Julie E. ;
Graham, Barney S. .
SCIENCE, 2019, 365 (6452) :505-+
[7]  
Eichinger Katherine M, 2021, Ther Adv Vaccines Immunother, V9, p2515135520981516, DOI 10.1177/2515135520981516
[8]  
EMA. Committee for Medicinal Products for Human Use, SUMM POS OP BEYF
[9]  
Ewer KJ., 2018, AM J TROP MED HYG, V99
[10]   An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults [J].
Falloon, Judith ;
Yu, Jing ;
Esser, Mark T. ;
Villafana, Tonya ;
Yu, Li ;
Dubovsky, Filip ;
Takas, Therese ;
Levin, Myron J. ;
Falsey, Ann R. .
JOURNAL OF INFECTIOUS DISEASES, 2017, 216 (11) :1362-1370